Antibodies to a novel antigen in acute hepatitis C virus infections.
Antibodies to a novel antigen in acute hepatitis C virus infections.
复制标题
急性丙型肝炎病毒感染中新抗原的抗体。
DOI：
10.1111/j.1423-0410.2006.00856.x
复制
发表时间：
2007
期刊：
影响因子：
2.7
通讯作者：
Busch,MP
中科院分区：
文献类型：
--
作者：
Tobler,LH;Stramer,SL;Chien,DY;Lin,S;Arcangel,P;Phelps,BH;Cooper,SL;Busch,MP
背景病毒构象蛋白在急性丙型肝炎病毒（HCV）感染的免疫生物学中可能起重要作用，并可能使早期抗体检测成为可能。使用三种酶免疫测定法（EIA）评价早期抗体产生，这些酶免疫测定法含有许可EIA中不存在的抗原蛋白。其中包括1个多表位融合抗原（MEFA）7·1-NS 3/4a、2个F和Core蛋白以及3个E1/E2蛋白。NS 3/4a是一种具有蛋白酶和解旋酶活性的构象抗原。MEFA 7·1包含许可EIA中使用的线性表位，包括最新的EIA-3·0，以及基因型1-3特异性表位。42份RNA阳性、EIA-3·0阴性样本（包括2例持续血清沉默病例）用于评价这些研究EIA。结果42例HCV RNA阳性标本中，仅7例（17%）MEFA 7·1-NS 3/4a EIA阳性，3例EIA-3·0阳性对照均阳性，54例EIA-3·0阴性/HCV RNA阴性对照均阴性。值得注意的是，7份样本中有6份（86%）有活动性肝炎的证据（ALT > 210 IU/l）。两个血清沉默的情况下，研究EIA negative.ConclusionA新的EIA与构象和线性表位检测HCV抗体在17%的病毒血症标本错过了标准参考EIA-3·0。我们的研究EIA似乎可以检测到更接近急性肝炎开始的HCV抗体。考虑到平均RNA阳性、抗体阴性窗口期为1056·4天，这17%的产率将转化为提前100天检测抗体。
BackgroundConformational viral proteins potentially play an important role in the immunobiology of acute hepatitis C virus (HCV) infection and may enable earlier antibody detection.Materials and MethodsHCV RNA was detected using nucleic acid testing. Early antibody production was evaluated using three enzyme immunoassays (EIAs) containing antigenic proteins not present in licensed EIAs. Respectively, these contained:1multiple‐epitope fusion antigen (MEFA) 7·1‐NS3/4a,2F and Core, and3E1/E2 proteins.NS3/4a is a conformational antigen retaining protease and helicase enzymatic activities. MEFA 7·1 contains the linear epitopes used in licenced EIAs, including the latest EIA‐3·0, in combination with genotype 1–3 specific epitopes. Forty‐two RNA positive, EIA‐3·0 negative samples, including two persistently serosilent cases, were used to evaluate these research EIAs. As controls, 54 EIA‐3·0 negative/RNA negative and three HCV RNA+/antibody positive specimens were included.ResultsOnly the MEFA 7·1‐NS3/4a EIA was positive in seven (17%) of the 42 HCV RNA + specimens, in all three EIA‐3·0 positive controls but in none of 54 EIA‐3·0 negative/HCV RNA negative controls. Notably, six of the seven (86%) specimens had evidence of active hepatitis (ALT > 210 IU/l). The two serosilent cases were research EIA negative.ConclusionA novel EIA with conformational and linear epitopes detected HCV antibodies in 17% of viraemic specimens missed by the standard reference EIA‐3·0. Our research EIA appears to detect HCV antibodies closer to the initiation of acute hepatitis. Given that the average RNA‐positive, antibody‐negative window period is ∼56·4 days, this 17% yield would translate into a ∼10‐day earlier detection of antibodies.